Loading
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Yizhong Pharmaceutical Co., Ltd., now recruiting.
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT06752811 by Shanghai Yizhong Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-02-05 and due to reach its primary completion in 2027-07-01. Interventions recorded: paclitaxel polymeric micelles for injection, Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (albumin bound ).
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.